These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
200 related items for PubMed ID: 27526944
1. New insights into the mode of action of the lantibiotic salivaricin B. Barbour A, Tagg J, Abou-Zied OK, Philip K. Sci Rep; 2016 Aug 16; 6():31749. PubMed ID: 27526944 [Abstract] [Full Text] [Related]
2. Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Geng M, Austin F, Shin R, Smith L. Appl Environ Microbiol; 2018 Mar 01; 84(5):. PubMed ID: 29269497 [Abstract] [Full Text] [Related]
3. Salivaricin D, a novel intrinsically trypsin-resistant lantibiotic from Streptococcus salivarius 5M6c isolated from a healthy infant. Birri DJ, Brede DA, Nes IF. Appl Environ Microbiol; 2012 Jan 01; 78(2):402-10. PubMed ID: 22101034 [Abstract] [Full Text] [Related]
4. Enhanced production, purification, characterization and mechanism of action of salivaricin 9 lantibiotic produced by Streptococcus salivarius NU10. Barbour A, Philip K, Muniandy S. PLoS One; 2013 Jan 01; 8(10):e77751. PubMed ID: 24147072 [Abstract] [Full Text] [Related]
5. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors. Müller A, Ulm H, Reder-Christ K, Sahl HG, Schneider T. Microb Drug Resist; 2012 Jun 01; 18(3):261-70. PubMed ID: 22432708 [Abstract] [Full Text] [Related]
6. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Tagg JR. Indian J Med Res; 2004 May 01; 119 Suppl():13-6. PubMed ID: 15232154 [Abstract] [Full Text] [Related]
7. Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Wescombe PA, Upton M, Renault P, Wirawan RE, Power D, Burton JP, Chilcott CN, Tagg JR. Microbiology (Reading); 2011 May 01; 157(Pt 5):1290-1299. PubMed ID: 21310787 [Abstract] [Full Text] [Related]
8. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C. Wiedemann I, Böttiger T, Bonelli RR, Schneider T, Sahl HG, Martínez B. Appl Environ Microbiol; 2006 Apr 01; 72(4):2809-14. PubMed ID: 16597986 [Abstract] [Full Text] [Related]
9. Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG. Antimicrob Agents Chemother; 1995 Mar 01; 39(3):714-9. PubMed ID: 7793878 [Abstract] [Full Text] [Related]
10. Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious Diseases. Barbour A, Wescombe P, Smith L. Trends Microbiol; 2020 Jul 01; 28(7):578-593. PubMed ID: 32544444 [Abstract] [Full Text] [Related]
11. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Wescombe PA, Upton M, Dierksen KP, Ragland NL, Sivabalan S, Wirawan RE, Inglis MA, Moore CJ, Walker GV, Chilcott CN, Jenkinson HF, Tagg JR. Appl Environ Microbiol; 2006 Feb 01; 72(2):1459-66. PubMed ID: 16461700 [Abstract] [Full Text] [Related]
12. Insights into the mode of action of the two-peptide lantibiotic haloduracin. Oman TJ, van der Donk WA. ACS Chem Biol; 2009 Oct 16; 4(10):865-74. PubMed ID: 19678697 [Abstract] [Full Text] [Related]
13. The lantibiotic NAI-107 binds to bactoprenol-bound cell wall precursors and impairs membrane functions. Münch D, Müller A, Schneider T, Kohl B, Wenzel M, Bandow JE, Maffioli S, Sosio M, Donadio S, Wimmer R, Sahl HG. J Biol Chem; 2014 Apr 25; 289(17):12063-12076. PubMed ID: 24627484 [Abstract] [Full Text] [Related]
14. Antimicrobial mechanism of lantibiotics. Islam MR, Nagao J, Zendo T, Sonomoto K. Biochem Soc Trans; 2012 Dec 01; 40(6):1528-33. PubMed ID: 23176511 [Abstract] [Full Text] [Related]
15. Characterization of salivaricin CRL 1328, a two-peptide bacteriocin produced by Lactobacillus salivarius CRL 1328 isolated from the human vagina. Vera Pingitore E, Hébert EM, Nader-Macías ME, Sesma F. Res Microbiol; 2009 Dec 01; 160(6):401-8. PubMed ID: 19591924 [Abstract] [Full Text] [Related]
16. Type AII lantibiotic bovicin HJ50 with a rare disulfide bond: structure, structure-activity relationships and mode of action. Zhang J, Feng Y, Teng K, Lin Y, Gao Y, Wang J, Zhong J. Biochem J; 2014 Aug 01; 461(3):497-508. PubMed ID: 24814218 [Abstract] [Full Text] [Related]
17. Salivaricin G32, a Homolog of the Prototype Streptococcus pyogenes Nisin-Like Lantibiotic SA-FF22, Produced by the Commensal Species Streptococcus salivarius. Wescombe PA, Dyet KH, Dierksen KP, Power DA, Jack RW, Burton JP, Inglis MA, Wescombe AL, Tagg JR. Int J Microbiol; 2012 Aug 01; 2012():738503. PubMed ID: 22567013 [Abstract] [Full Text] [Related]
18. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Wiedemann I, Böttiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG. Mol Microbiol; 2006 Jul 01; 61(2):285-96. PubMed ID: 16771847 [Abstract] [Full Text] [Related]
19. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR. Appl Environ Microbiol; 2007 Feb 01; 73(4):1107-13. PubMed ID: 17194838 [Abstract] [Full Text] [Related]
20. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Bonelli RR, Schneider T, Sahl HG, Wiedemann I. Antimicrob Agents Chemother; 2006 Apr 01; 50(4):1449-57. PubMed ID: 16569864 [Abstract] [Full Text] [Related] Page: [Next] [New Search]